Atomi Financial Group Inc. Acquires 4,189 Shares of Sanofi (NASDAQ:SNY)

Atomi Financial Group Inc. grew its holdings in Sanofi (NASDAQ:SNY) by 26.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,932 shares of the company’s stock after acquiring an additional 4,189 shares during the quarter. Atomi Financial Group Inc.’s holdings in Sanofi were worth $1,149,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. POM Investment Strategies LLC acquired a new stake in shares of Sanofi during the second quarter worth $25,000. Register Financial Advisors LLC bought a new stake in shares of Sanofi in the first quarter valued at about $29,000. Larson Financial Group LLC lifted its holdings in shares of Sanofi by 480.8% in the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after purchasing an additional 500 shares in the last quarter. Palisade Asset Management LLC bought a new stake in shares of Sanofi in the first quarter valued at about $31,000. Finally, Arrow Financial Corp bought a new stake in shares of Sanofi in the second quarter valued at about $35,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Up 0.2 %

NASDAQ:SNY opened at $54.85 on Wednesday. Sanofi has a twelve month low of $42.63 and a twelve month high of $58.97. The firm has a market capitalization of $138.92 billion, a price-to-earnings ratio of 27.56, a price-to-earnings-growth ratio of 1.58 and a beta of 0.60. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The stock’s 50 day moving average price is $55.58 and its two-hundred day moving average price is $51.19.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.95 earnings per share. Equities research analysts expect that Sanofi will post 4.26 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of research reports. Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.